Taro Receives FDA Approval for Ciclopirox and Loratadine Syrup
Posted on: Monday, 24 September 2007, 15:00 CDT
Pharmaceutical company Taro has received FDA approval for its abbreviated new drug application for ciclopirox topical solution, and supplemental abbreviated new drug application for loratadine syrup, an over-the-counter product.
Ciclopirox nail lacquer is a prescription pharmaceutical product used for the topical treatment of onychomycosis. Taro says the FDA has determined that its ciclopirox nail lacquer is safe and effective for use when compared with the reference-listed drug product, Penlac Nail Lacquer, topical solution 8%, of Sanofi-Aventis.
The first grape flavored loratadine syrup is bioequivalent to Schering's Claritin syrup and is used for the relief of symptoms due to seasonal allergic rhinitis. Taro believes that this formulation has an annual US sales of approximately $25 million.
Source: Datamonitor
Related Articles
- CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
- Asymchem Announces sFDA Certification for Drug Product Manufacturing
- Asymchem Announces Opening of High Potency API and Drug Product Facility
- White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product
- RegeneRx Names Drug Products Under Clinical Development
- Akorn and Cipla to Develop Inhalation Drug Product
- Akorn, Inc. And Natco Pharma Limited Add Two Injectable Drug Products To API Supply and Margin Sharing Agreement
- The Most Efficient Way to Get Your Food and Drug Products to Market Within FDA Regulations
- FDA Provides Clearance to Initiate Phase I Clinical Trial With Alzheimer's Disease Drug Product AZD-103
- OSEL In-Licenses Therapeutic Drug Product From Japan
 |
 |
User Comments (0)
RSS Feeds